MaxCyte, Inc.

NasdaqGS MXCT

MaxCyte, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -2.42 M

MaxCyte, Inc. Capital Expenditure is USD -2.42 M for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

MaxCyte, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -17.40 M, a -466.77% change year over year.
MaxCyte, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -3.07 M, a -47.45% change year over year.
MaxCyte, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -2.08 M, a -87.35% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: MXCT

MaxCyte, Inc.

CEO	Mr. Maher Masoud
IPO Date	July 30, 2021
Location	United States
Headquarters	9713 Key West Avenue
Employees	143
Sector	Healthcare
Industries Biotechnology 3D Printing

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key trends

Past 5 years